Clinical diabetes : a publication of the American Diabetes Association · 2025
Assessing the iLet Bionic Pancreas Deployed in Primary Care and via Telehealth: A Randomized Clinical Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oser Sean M, Putman Melissa S, Russell Steven J, Westfeldt Elizabeth B, Huss Kelsey B, Prince Britney K, Parascando Jessica A, O'Connor Mollie Y, Sabean Amy, Ashley Annabelle L, Greaux Evelyn G, Bartholomew Rachel J, Gaston Sarah, Anandakugan Nillani, Zheng Hui, Balliro Courtney A, Hillard Mallory A, Damiano Edward R, Oser Tamara K
Аннотация
The iLet Bionic Pancreas system can improve glycemia in individuals with type 1 diabetes with its simple interface, setup, and maintenance, making it practical for use in the primary care setting and via telehealth (TH). This multisite, random-order crossover trial included 40 adults with type 1 diabetes who received care either from an endocrinology or a primary care clinic and were seen either in person or via TH. Of these 40 participants, 97% achieved an average glucose (AG) <183 mg/dL, and 64% achieved an AG <154 mg/dL. These results suggest that the system can be initiated effectively by primary care providers and via TH, potentially expanding access to this technology to a broad population, including individuals who cannot easily access subspecialty diabetes care.